The objectives of the presentation are:

1.  Discuss the Alzheimer disease cognitive spectrum from Subjective Cognitive Decline to Mild Cognitive Impairment to Dementia

2.  Review CCCDTD5 guidance on tools and approaches for dementia assessments

Summary: We will review the evolution of Alzheimer's disease, highlighting opportunities for early detection. Additionally, we will walk through the CCCDTD5 guidelines on dementia assessments, focusing on principles, tools, and sources of information, to best detect AD early.

This integrated KTE webinar event is brought to you by brainXchange in partnership with the Alzheimer Society of Canada and the Canadian Consortium of Neurodegeneration in Aging (CCNA)


Event Date: May 06, 2021

Related Resources l Recording



Zahinoor Ismail MD, Associate Professor Psychiatry, Neurology, and Epidemiology
Hotchkiss Brain Institute & O'Brien Institute for Public Health, University of Calgary

Dr Zahinoor Ismail is a Clinician Scientist and Associate Professor of Psychiatry, Neurology, and
Epidemiology at the Hotchkiss Brain Institute and O’Brien Institute for Public Health, at the
University of Calgary. He has certification in Behavioral Neurology & Neuropsychiatry, and Geriatric Psychiatry, and his dementia research includes: i) rating scale development and measurement-based care; ii) non-cognitive markers of dementia; iii) neuroimaging and biomarker studies; and iv) clinical trials. He is funded by Brain Canada, the Canadian Institutes of Health Research, and the Canadian Consortium on Neurodegeneration in Aging.

Dr. Ismail is Academic Chair of the Alzheimer’s Association-ISTAART Neuropsychiatric Symptoms Professional Interest Area, Chair of the Canadian Conference on Dementia, and Co-Chair of the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, which generates Canadian dementia guidelines, the most recent iteration of which were published in 2020. Dr Ismail led the ISTAART development of the neurobehavioural syndrome Mild Behavioural Impairment (MBI) and the MBI Checklist, and co-led development of the new research criteria for biomarker and phenotypic classification of psychosis in AD and related dementias.